

Severe Asthma Index Country Questionnaire

Welcome to the Severe Asthma Index Country Questionnaire. Your response will help maximise the impact of the Severe Asthma Index and support positive, data-driven developments in the severe asthma space for both health systems and patients, as well as highlight the importance and utility of country health system data.


The questionnaire takes 30 to 40 minutes to answer. **Please note that you may not be able to answer all questions in every section of the questionnaire. Several experts with different professional backgrounds have been contacted for each country featured in the Severe Asthma Index to ensure that a complete set of responses can be collected.**

All personal identifiers linked questionnaire responses will be anonymised upon publication of the Severe Asthma Index. However, the Copenhagen Institute for Futures Studies may contact you and other respondents while the Index is still in production if further clarification of responses is required.

Any inquiries regarding this questionnaire or the Severe Asthma Index in general can be directed to Patrick Gallen, Data Lead for the Severe Asthma Index, at phg@cifs.dk.

 required

Respondent information

1. Enter your name 

2. Profession *

3. Organisation *

4. On behalf of which country are you providing responses? *

- Australia
- Austria
- Belgium
- Canada
- Czechia
- Denmark
- Estonia
- Finland
- France
- Germany
- Greece
- Hungary
- Ireland
- Italy
- Japan
- Latvia
- Lithuania
- Netherlands
- New Zealand
- Norway

5. Please select the entry that most closely aligns with your professional background: *

- Medical professional
- Policy specialist/policymaker
- Patient representative
- Other

- Switzerland
- United Kingdom

Health system characteristics

6. What is the annual number of hospitalisations attributed to severe asthma? (Please provide data from the latest possible year.)

The value must be a number

7. From which year is this data?

The value must be a number

8. What is the number of emergency room visits attributed to severe asthma exacerbations? (Please provide data from the latest possible year.)

The value must be a number

9. From which year is this data?

The value must be a number

10. What is the average number of nights spent in hospital when severe asthma patients are hospitalised? (Please provide data from the latest possible year.)

The value must be a number

11. What is the average cost per severe asthma patient per year for the public healthcare system in your country? (In local currency.)

12. How many operational severe asthma units exist in your country currently?

The value must be a number

13. Are there plans to open additional severe asthma units in the next five years in your country? *

- Yes
- No
- I don't know

14. How many rescue inhalers are prescribed annually? (Please provide data from the latest possible year.)

The value must be a number

15. How many people are taking at least 3 courses of OCS (oral corticosteroids) annually? (Please provide data from the latest possible year.)

The value must be a number

16. How many asthma exacerbations have been recorded in your country? (Please provide data from the latest complete year.)

17. Do standardised referral pathways from primary to specialist care for severe asthma patients exist in your country? *

- Yes
- No
- I don't know

18. Can patients access specialist care without a referral in your country? *

- Yes
- Yes, only private specialist care
- No
- I don't know

19. Approximately what percentage of asthma patients have direct access to respiratory units in your country?

- 0%
- 1-10%
- 11-20%
- 21-30%
- 31-40%
- 41-50%
- 51-60%
- 61-70%
- 71-80%
- 81-90%
- 91-100%
- I don't know

20. Is there a national guideline for management of severe asthma exacerbations in the emergency room? *

- Yes
- No
- I don't know

21. Is there a national guideline for follow-up for severe asthma patients that includes utilisation of primary care after an emergency room visit? *

- Yes
- No
- I don't know

22. Is there a standardised treatment regimen for patients diagnosed with severe asthma in your country? *

- Yes
- No
- I don't know

23. Please provide details about this treatment regimen.

24. Are individualised or stratified treatment regimines made for severe asthma patients in your country? *

- Yes
- No
- I don't know

25. Is weight reduction included by default in condition management plans for high-BMI severe asthma patients in your country? *

- Yes
- No
- I don't know

26. Is fractional exhaled nitric oxide (FeNO) used to assess risk of future asthma attacks and/or medication adherence in your country? *

- Yes, only for assessing risk of future asthma attacks
- Yes, only for medication adherence
- Yes, for both
- No, FeNO is not used for either purpose
- I don't know

27. Are any of the following biologics used in the treatment of severe asthma in your country? (Please select all that apply.) *

- Xolair (omalizumab)
- Nucala (mepolizumab)
- Dupixent (dupilumab)
- Cinqair (reslizumab)
- Fasenra (benralizumab)
- Tezspire (tezepelumab)
- None of the above
- I don't know

28. Are clinicians in your country required to track and record severe asthma patients' adherence to treatment and management regimens? *

- Yes, at all care centres
- Yes, at some care centres
- No
- I don't know

29. How is medication adherence tracked? (Please provide as much detail as possible.)

30. Is pharmacogenetic screening used in clinical settings concerning severe asthma in your country? *

- Yes
- No
- I don't know

31. Since which year has pharmacogenetic screening been used?

The value must be a number

32. Are patient outcomes related to the treatment of severe asthma formally reported to any health data registry? *

- Yes, an international/multi-country registry
- Yes, a national registry
- Yes, a subnational registry
- No
- I don't know

33. Since which year have patient outcomes for severe asthma been recorded?

The value must be a number

34. Data concerning patient outcomes for severe asthma in my country are disaggregated by (select all that apply): *

- Age
- Sex
- Income bracket
- Race/ethnicity
- Geographical location
- All of the above
- None of the above
- I don't know
- Other

35. Are there plans to record patient outcomes in the future? *

- Yes
- No
- I don't know

36. When is the recording of patient outcomes for severe asthma planned to begin?

37. Data concerning hospitalisation for severe asthma in my country are disaggregated by (select all that apply): *

- Age
- Sex
- Income bracket
- Race/ethnicity
- Geographical location
- All of the above
- None of the above
- I don't know
- Other

38. Data concerning medication provision for severe asthma patients in my country are disaggregated by (select all that apply): *

- Age
- Sex
- Income bracket
- Race/ethnicity
- Geographical location
- All of the above
- I don't know
- Other

Policy Context

39. Does your country have specific care guidelines for severe asthma? *

- Yes
- No
- I don't know

40. On which level are these care guidelines implemented?

- National
- Regional
- Local
- I don't know
- Other

41. When were the guidelines first implemented?

The value must be a number

42. When will the guidelines be updated next?

43. Do the guidelines adhere to any of the following aspects of the GINA guidelines for "difficult-to-treat asthma"? Please select all that apply.

- For adolescents and adults with symptoms and/or exacerbations despite medium or high dose ICS-LABA or taking maintenance OCS?
- In diagnosis and treatment of severe asthma phenotypes?
- For treatment tracks including personal control-based asthma management?
- For management of worsening asthma and exacerbations?
- None of the above
- I don't know
- Other

44. Which, if any, of the methods listed below are used to assess the inflammatory phenotype of asthma patients in your country? Please select all that apply. *

- Spirometry
- Fractional Exhaled Nitric Oxide (FeNO)
- Assessment of immunoglobulin E (IgE) levels
- Allergy testing
- Gas diffusion test
- X-ray imaging
- None of the above

45. Does your country have a national strategy for asthma? *

- Yes
- No
- I don't know

46. To what extent is the national strategy implemented?

- Fully implemented
- Under implementation
- Under approval process
- In development
- Planned, but development not initiated
- I don't know

47. Are there plans to update this strategy in the future?

- Yes
- No
- I don't know

48. When is the strategy planned to be updated?

The value must be a number

49. Does the national strategy include elements specifically related to severe asthma?

- Yes
- No
- I don't know

50. Does the strategy address external environmental factors such as air quality and pollution?

- Yes
- No
- I don't know

51. Do any government authorities in your country regularly perform assessments of the effectiveness and safety of health technologies related to tools, services, and/or treatments related to the diagnosis or management of severe asthma? *

- Yes
- No
- I don't know

Access and Care Coverage

52. Which of the following classes of drugs/treatments/diagnostics are partially or fully covered by the public health insurance scheme(s) in your country? *

	Full coverage	Partial coverage	No coverage	I don't know
Fractional Exhaled Nitric Oxide (FeNO) testing	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Inhaled corticosteroids (ICS)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Oral corticosteroids (OCS)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Intravenous corticosteroids	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Leukotrine modifiers	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Combination inhalers	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Short-acting beta agonists (SABA)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Long-acting beta agonists (LABA)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Short-acting muscarinic agents (SAMA)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Long-acting muscarinic agents (LAMA)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

53. If possible, please provide information about how much public/national health insurance coverage is provided for classes of drugs/treatments/diagnostics where "partial coverage" is selected.

54. Are patient co-pays required for any of the above classes of drugs/treatments/diagnostics? (Please provide as much detail as possible.)

55. Which of the following biologics are partially or fully covered by the public health insurance scheme(s) in your country? *

	Full coverage	Partial coverage	No coverage	I don't know
Xolair (omalizumab)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Nucala (mepolizumab)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Dupixent (dupilumab)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Cinqair (reslizumab)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Fasenra (benralizumab)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Tezspire (tezepelumab)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

56. If possible, please provide information about how much public/national health insurance coverage is provided for biologics where "partial coverage" is selected.

57. Are patient co-pays required for any of the above biologics? (Please provide as much detail as possible.)

58. Does any public authority in your country engage in or make decisions about rationing of drugs used to treat or manage severe asthma? *

- Yes
- No
- I don't know

59. How is public payor coverage for specialist care for severe asthma patients best characterised in your country? *

- Full public insurance coverage for specialist care
- Partial public insurance coverage for specialist care
- No public insurance coverage for specialist care
- I don't know

Digital care and therapeutics

60. Can patients receive telemedicine/remote care for severe asthma in your country? *

- Yes
- No
- I don't know

61. Is telemedicine for severe asthma patients covered by the public insurance system in your country?

- Yes, fully covered
- Yes, partially covered
- No coverage
- I don't know

62. Are digital therapeutics (DTx) such as smart inhalers and apps approved for management of severe asthma in your country? *

- Yes
- No
- I don't know

63. Are digital therapeutics for severe asthma patients covered by the public insurance system in your country?

- Yes, fully covered
- Yes, partially covered
- No coverage
- I don't know

Thank you for your response!

Your contribution to the Severe Asthma Index is greatly appreciated. If you have any inquiries regarding the Severe Asthma Index or this questionnaire, please contact Patrick Henry Gallen, Data Lead at phg@cifs.dk.

64. I would like to receive updates regarding the Severe Asthma Index: *

Yes

No

65. I would like to receive more information about the Copenhagen Institute for Futures Studies, which is responsible for the collection and generation of the data that will be featured in the Severe Asthma Index: *

Yes

No

This content is neither created nor endorsed by Microsoft. The data you submit will be sent to the form owner.

 Microsoft Forms